A critical role for Egr-1 during vascular remodelling in pulmonary arterial hypertension

Michael G. Dickinson*, Piotr S. Kowalski, Beatrijs Bartelds, Marinus A. J. Borgdorff, Diederik van der Feen, Hannie Sietsma, Grietje Molema, Jan A. A. M. Kamps, Rolf M. F. Berger

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

33 Citations (Scopus)

Abstract

Aims Pulmonary arterial hypertension (PAH) is characterized by the development of unique neointimal lesions in the small pulmonary arteries, leading to increased right ventricular (RV) afterload and failure. Novel therapeutic strategies are needed that target these neointimal lesions. Recently, the transcription factor Egr-1 (early growth response protein 1) was demonstrated to be up-regulated early in experimental neointimal PAH. Its effect on disease development, however, is unknown. We aimed to uncover a novel role for Egr-1 as a molecular inductor for disease development in PAH.

Methods and results In experimental flow-associated PAH in rats, we investigated the effects of Egr-1 down-regulation on pulmonary vascular remodelling, including neointimal development, and disease progression. Intravenous administration of catalytic oligodeoxynucleotides (DNA enzymes, DNAzymes) resulted in down-regulation of pulmonary vascular Egr-1 expression. Compared with vehicle or scrambled DNAzymes, DNAzymes attenuated pulmonary vascular remodelling, including the development of occlusive neointimal lesions. Selective down-regulation of Egr-1 in vivo led to reduced expression of vascular PDGF-beta, TGF-beta, IL-6, and p53, resulting in a reduction of vascular proliferation and increased apoptosis. DNAzyme treatment further attenuated pulmonary vascular resistance, RV systolic pressure, and RV hypertrophy. In contrast, in non-neointimal PH rodents, DNAzyme treatment had no effect on pulmonary vascular and RV remodelling. Finally, pharmacological inhibition of Egr-1 with pioglitazone, a peroxisome proliferator activated receptor-g ligand, attenuated vascular remodelling including the development of neointimal lesions.

Conclusions These results indicate that Egr-1 governs pulmonary vascular remodelling and the development of characteristic vascular neointimal lesions in flow-associated PAH. Egr-1 is therefore a potential target for future PAH treatment.

Original languageEnglish
Pages (from-to)573-584
Number of pages12
JournalCardiovascular Research
Volume103
Issue number4
DOIs
Publication statusPublished - 1-Sep-2014

Keywords

  • Congenital heart disease
  • Right ventricular failure
  • Pulmonary vascular remodeling
  • Endothelial cell
  • Proliferation
  • ACTIVATED RECEPTOR-GAMMA
  • EARLY GROWTH
  • ENDOTHELIAL-CELLS
  • RIGHT VENTRICLE
  • ANIMAL-MODELS
  • DNA ENZYMES
  • IN-VIVO
  • PROLIFERATION
  • RESPONSE-1
  • INHIBITION

Cite this